X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (418) 418
Publication (76) 76
Book Review (6) 6
Book Chapter (5) 5
Dissertation (4) 4
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clofarabine (398) 398
humans (273) 273
index medicus (252) 252
oncology (177) 177
hematology (161) 161
male (126) 126
female (120) 120
cancer (95) 95
arabinonucleosides - administration & dosage (92) 92
middle aged (91) 91
adult (85) 85
adenine nucleotides - administration & dosage (83) 83
acute myeloid-leukemia (82) 82
aged (80) 80
chemotherapy (80) 80
leukemia, myeloid, acute - drug therapy (79) 79
arabinonucleosides - therapeutic use (75) 75
acute myeloid leukemia (74) 74
treatment outcome (74) 74
leukemia (70) 70
cytarabine (69) 69
antineoplastic combined chemotherapy protocols - therapeutic use (65) 65
arabinonucleosides - adverse effects (63) 63
transplantation (63) 63
adenine nucleotides - therapeutic use (62) 62
article (60) 60
fludarabine (60) 60
adenine nucleotides - adverse effects (58) 58
adolescent (54) 54
antineoplastic agents (50) 50
child (49) 49
children (49) 49
pediatric-patients (49) 49
remission induction (49) 49
antimitotic agents (48) 48
arabinonucleosides - pharmacology (47) 47
pharmacology & pharmacy (46) 46
young adult (46) 46
acute myelogenous leukemia (45) 45
cladribine (44) 44
recurrence (44) 44
acute lymphoblastic-leukemia (43) 43
antineoplastic agents - therapeutic use (43) 43
research (43) 43
therapy (43) 43
hematology, oncology and palliative medicine (42) 42
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (42) 42
ribonucleotide reductase (41) 41
aml (40) 40
child, preschool (39) 39
adenine nucleotides - pharmacology (38) 38
animals (37) 37
leukemia, myeloid, acute - mortality (37) 37
antineoplastic combined chemotherapy protocols - adverse effects (36) 36
stem cells (35) 35
care and treatment (34) 34
nucleoside analog (34) 34
pediatrics (34) 34
chronic lymphocytic-leukemia (33) 33
cyclophosphamide (32) 32
cytarabine - administration & dosage (32) 32
cell line, tumor (31) 31
combination (31) 31
nucleoside analogs (31) 31
relapse (30) 30
antineoplastic agents - pharmacology (29) 29
myelodysplastic syndrome (29) 29
phase-ii (29) 29
hematopoietic stem cells (28) 28
older patients (28) 28
aged, 80 and over (27) 27
arabinonucleosides - pharmacokinetics (27) 27
dose-response relationship, drug (27) 27
etoposide (27) 27
busulfan (26) 26
phase-i (26) 26
stem-cell transplantation (26) 26
adenine nucleotides (25) 25
adults (25) 25
health aspects (25) 25
hematopoietic stem cell transplantation (25) 25
survival analysis (25) 25
acute lymphoblastic leukemia (24) 24
analysis (24) 24
antimetabolites, antineoplastic - therapeutic use (24) 24
biochemistry & molecular biology (24) 24
clinical trials as topic (24) 24
infant (24) 24
leukemia, myeloid, acute - therapy (24) 24
medicine & public health (24) 24
prognosis (24) 24
salvage therapy (24) 24
transplantation, homologous (24) 24
nelarabine (23) 23
risk myelodysplastic syndrome (23) 23
vidarabine - analogs & derivatives (23) 23
retrospective studies (22) 22
survival (22) 22
2-chloro-9-adenine (21) 21
cytarabine - adverse effects (21) 21
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (416) 416
French (3) 3
Polish (3) 3
Korean (2) 2
Chinese (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6175 - 6184
Purpose: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell therapy approved for the treatment of children and young adults with... 
CLOFARABINE | ONCOLOGY | T-CELLS | PEDIATRIC-PATIENTS
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 01/2012, Volume 46, Issue 1, pp. 89 - 96
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 18, pp. 1788 - 1797
PurposeThe aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute... 
CLOFARABINE | THERAPY | ONCOLOGY | CLONAL HEMATOPOIESIS | PERSISTENCE | MONOSOMAL KARYOTYPE | FLOW-CYTOMETRY | DNMT3A MUTATIONS | MINIMAL RESIDUAL DISEASE | CANCER | ADULT | RAPID COMMUNICATION
Journal Article
Clinical lymphoma, myeloma & leukemia, ISSN 2152-2650, 6/2014, Volume 14, Issue 3, pp. 231 - 238
Journal Article
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 9/2017, Volume 23, Issue 17, pp. 5225 - 5237
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2018, Volume 36, Issue 32, pp. 3192 - 3202
PurposeThe anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute... 
CLOFARABINE | ETOPOSIDE | ECONOMIC-EVALUATION | ONCOLOGY | CYCLOPHOSPHAMIDE | TRANSPLANT | TISAGENLECLEUCEL | QUALITY-OF-LIFE | HEALTH | TERM SURVIVORS | CHILDREN
Journal Article
BMB Reports, ISSN 1976-6696, 2015, Volume 48, Issue 3, pp. 166 - 171
We previously demonstrated that resveratrol and clofarabine elicited a marked cytotoxicity on malignant mesothelioma (MM) MSTO-211H cells but not on the... 
MSTO-211H | Chemosensitivity | Clofarabine | MeT-5A | Resveratrol
Journal Article
JNCI: Journal of the National Cancer Institute, ISSN 0027-8874, 07/2019, Volume 111, Issue 7, pp. 719 - 726
Abstract Background Chimeric antigen receptor T-cell (CAR-T) therapy is a promising new class of cancer therapy but has a high up-front cost. We evaluated the... 
BREAST-CANCER | CLOFARABINE | ETOPOSIDE | STATES | ONCOLOGY | CYCLOPHOSPHAMIDE | QUALITY-OF-LIFE | HEALTH | CHEMOTHERAPY | ECONOMIC BURDEN | CHILDREN
Journal Article
Oncotarget, ISSN 1949-2553, 09/2018, Volume 9, Issue 71, pp. 33528 - 33535
The Baltimore reduced-intensity conditioning (RIC) regimen using high-dose post-transplant cyclophosphamide (PTCY) is considered as a standard of care for... 
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 07/2018, Volume 140, Issue 28, pp. 8797 - 8806
The utilization of nanotechnology for the delivery of a wide range of anticancer drugs has the potential to reduce adverse effects of free drugs and improve... 
THERAPEUTICS | CLOFARABINE | NANOPARTICLES | DESIGN | HYPERBRANCHED POLYMERS | DRUG-DELIVERY | DNA | NANOMATERIALS | NANOMEDICINE | NANOSTRUCTURES | CHEMISTRY, MULTIDISCIPLINARY | Index Medicus
Journal Article
Leukemia Research Reports, ISSN 2213-0489, 2017, Volume 7, pp. 14 - 16
We describe a relapsed AML patient who had two prior severe reactions to clofarabine involving rigors, emesis, tachycardia, hypotension, and acute kidney... 
Clofarabine | Acute Myeloid Leukemia | Desensitization
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 06/2018, Volume 78, Issue 6, pp. 1047 - 1056
A definitive diagnosis of Langerhans cell histiocytosis (LCH) requires a combination of clinical presentation, histology, and immunohistochemistry. The... 
cytarabine | clofarabine | cladribine | diabetes insipidus | Langerhans cell histiocytosis | vinblastine | BRAF | steroids
Journal Article
Chinese Journal of Organic Chemistry, ISSN 0253-2786, 2014, Volume 34, Issue 6, pp. 1154 - 1160
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.